Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9

Biochemical and Biophysical Research Communications

Volumn 322, Issue 3, 2004, Pages 836-841

  Bhattacharjee, Hiranmoy ^a   Carbrey, Jennifer ^b   Rosen, Barry P ^a   Mukhopadhyay, Rita ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimonite; Aquaglyceroporin; Arsenite; Leukemia

Indexed keywords

AQUAGLYCEROPORIN; AQUAGLYCEROPORIN 9; ARSENIC TRIOXIDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REGULATORY MECHANISM;

AQUAPORINS; ARSENICALS; BIOLOGICAL TRANSPORT; CLONING, MOLECULAR; HL-60 CELLS; HUMANS; ION CHANNELS; K562 CELLS; KINETICS; OXIDES; RECOMBINANT PROTEINS; TRANSFECTION; VITAMIN D;

EID: 4444263346     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.08.002     Document Type: Article

References (31)

1. P. La Rosee, K. Johnson, A.S. Corbin, E.P. Stoffregen, E.M. Moseson, S. Willis, M.M. Mauro, J.V. Melo, M.W. Deininger, and B.J. Druker In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines Blood 103 2004 208 215
2. M.A. Hussein Trials of arsenic trioxide in multiple myeloma Cancer Cont. 10 2003 370 374
3. S. Waxman, and K.C. Anderson History of the development of arsenic derivatives in cancer therapy Oncologist 6 2001 3 10
4. M. Borgnia, S. Nielsen, A. Engel, and P. Agre Cellular and molecular biology of the aquaporin water channels Ann. Rev. Biochem. 68 1999 425 458
5. P. Agre, L.S. King, M. Yasui, W.B. Guggino, O.P. Ottersen, Y. Fujiyoshi, A. Engel, and S. Nielsen Aquaporin water channels - from atomic structure to clinical medicine J. Physiol. 542 2002 3 16
6. O.I. Sanders, C. Rensing, M. Kuroda, B. Mitra, and B.P. Rosen Antimonite is accumulated by the glycerol facilitator GlpF in Escherichia coli J. Bacteriol. 179 1997 3365 3367
7. Z. Liu, J. Shen, J.M. Carbrey, R. Mukhopadhyay, P. Agre, and B.P. Rosen Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9 Proc. Natl. Acad. Sci. USA 99 2002 6053 6058
8. H. Tsukaguchi, S. Weremowicz, C.C. Morton, and M.A. Hediger Functional and molecular characterization of the human neutral solute channel aquaporin-9 Am. J. Physiol. 277 1999 F685 F696
9. K. Ishibashi, T. Morinaga, M. Kuwahara, S. Sasaki, and M. Imai Cloning and identification of a new member of water channel (AQP10) as an aquaglyceroporin Biochim. Biophys. Acta 1576 2002 335 340
10. J.M. Carbrey, D.A. Gorelick-Feldman, D. Kozono, J. Praetorius, S. Nielsen, and P. Agre Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver Proc. Natl. Acad. Sci. USA 100 2003 2945 2950
11. Z. Liu, J.M. Carbrey, P. Agre, and B.P. Rosen Arsenic trioxide uptake by human and rat aquaglyceroporins Biochem. Biophys. Res. Commun. 316 2004 1178 1185
12. A. Ramirez-Solis, R. Mukopadhyay, B.P. Rosen, and T.L. Stemmler Experimental and theoretical characterization of arsenite in water: insights into the coordination environment of As-O Inorg. Chem. 43 2004 2954 2959
13. Y.L. Meng, Z. Liu, and B.P. Rosen As(III) and Sb(III) Uptake by GlpF and Efflux by ArsB in Escherichia coli J. Biol. Chem. 279 2004 18334 18341
14. P.F. Reay, and C.J. Asher Preparation and purification of 74As-labeled arsenate and arsenite for use in biological experiments Anal. Biochem. 78 1977 557 560
15. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
16. P. Li, A.N. Uddin, Z. Liu, R. Mukhopadhyay, E.V. Komissarova, B.P. Rosen, and T.G. Rossman Variability in sensitivity to arsenite does not correlate with arsenic accumulation rate in normal human lymphoblasts Mol. Cell. Biochem. 255 2004 79 85
17. N. Ahmed, and M.V. Berridge N-glycosylation of glucose transporter-1 (Glut-1) is associated with increased transporter affinity for glucose in human leukemic cells Leuk. Res. 23 1999 395 401
18. H. Kuriyama, I. Shimomura, K. Kishida, H. Kondo, N. Furuyama, H. Nishizawa, N. Maeda, M. Matsuda, H. Nagaretani, S. Kihara, T. Nakamura, Y. Tochino, T. Funahashi, and Y. Matsuzawa Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9 Diabetes 51 2002 2915 2921
19. M.M. Rahman, U.K. Chowdhury, S.C. Mukherjee, B.K. Mondal, K. Paul, D. Lodh, B.K. Biswas, C.R. Chanda, G.K. Basu, K.C. Saha, S. Roy, R. Das, S.K. Palit, Q. Quamruzzaman, and D. Chakraborti Chronic arsenic toxicity in Bangladesh and West Bengal, India - a review and commentary J. Toxicol. Clin. Toxicol. 39 2001 683 700
20. C. Niu, H. Yan, T. Yu, H.P. Sun, J.X. Liu, X.S. Li, W. Wu, F.Q. Zhang, Y. Chen, L. Zhou, J.M. Li, X.Y. Zeng, R.R. Yang, M.M. Yuan, M.Y. Ren, F.Y. Gu, Q. Cao, B.W. Gu, X.Y. Su, G.Q. Chen, S.M. Xiong, T. Zhang, S. Waxman, Z.Y. Wang, and S.J. Chen Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients Blood 94 1999 3315 3324
21. P.H. Wiernik, J.P. Dutcher, R. Gallagher, G. Caliendo, S. Garl, and E. Paietta Phase II trial of arsenic trioxide in patients with relapsed/refractory acute myeloid leukemia, blast crisis of CML, or myelodysplasia Blood 94 Suppl. 1 1999 510a
22. D. Unnikrishnan, J.P. Dutcher, N. Varshneya, R. Lucariello, M. Api, S. Garl, P.H. Wiernik, and S. Chiaramida Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide Blood 97 2001 1514 1516
23. T.M. Beer, and A. Myrthue Calcitriol in cancer treatment: from the lab to the clinic Mol. Cancer Ther. 3 2004 373 381
24. N.J. Bahlis, J. McCafferty-Grad, I. Jordan-McMurry, J. Neil, I. Reis, M. Kharfan-Dabaja, J. Eckman, M. Goodman, H.F. Fernandez, L.H. Boise, and K.P. Lee Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma Clin. Cancer Res. 8 2002 3658 3668
25. T. Bachleitner-Hofmann, B. Gisslinger, E. Grumbeck, and H. Gisslinger Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br. J. Haematol. 112 2001 783 786
26. L. Michel, A. Dupuy, F. Jean-Louis, A. Sors, J. Poupon, M. Viguier, P. Musette, L. Dubertret, L. Degos, H. Dombret, and H. Bachelez Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C) J. Invest. Dermatol. 121 2003 881 893
27. A. Zittermann Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr. 89 2003 552 572
28. Q.M. Wang, J.B. Jones, and G.P. Studzinski Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells Cancer Res. 56 1996 264 267
29. M. Liu, M.H. Lee, M. Cohen, M. Bommakanti, and L.P. Freedman Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937 Genes Dev. 10 1996 142 153
30. D.M. McCarthy, J.F. San Miguel, H.C. Freake, P.M. Green, H. Zola, D. Catovsky, and J.M. Goldman 1,25-Dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells Leuk. Res. 7 1983 51 55
31. Y. Ji, and G.P. Studzinski Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells Cancer Res. 64 2004 370 377